कृपया अन्य खोज का प्रयास करें
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Lauren Lee | - | - | Board Observer |
Thilo Schroeder | 41 | - | Board Observer |
Krishnan Viswanadhan | 45 | 2022 | Independent Director |
Andras Attila Heczey | - | 2023 | Member of Scientific Advisory Board |
Marcela V. Maus | 47 | 2023 | Member Scientific Advisory Board |
Reid M. Huber | 51 | 2023 | Independent Director |
David C. Lubner | 59 | 2023 | Independent Director |
Cameron J. Turtle | - | 2023 | Member of Scientific Advisory Board |
Abraham Bassan | 39 | 2021 | Director |
Stephen Gottschalk | - | 2023 | Member of Scientific Advisory Board |
Kapil Dhingra | 65 | 2024 | Director |
Robbie Majzner | - | 2023 | Founder & Chair of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है